Hypermethylation of the GABRẼmiR-452̃miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2169-2181

  Kristensen, Helle ^a   Haldrup, Christa ^a   Strand, Siri ^a   Mundbjerg, Kamilla ^a   Mortensen, Martin M ^a   Thorsen, Kasper ^a   Ostenfeld, Marie Stampe ^a   Wild, Peter J ^b   Arsov, Christian ^c   Goering, Wolfgang ^c   Visakorpi, Tapio ^d   Egevad, Lars ^e   Lindberg, Johan ^e   Grönberg, Henrik ^e   Høyer, Søren ^a   Borre, Michael ^a   Orntoft, Torben F ^a   Sørensen, Karina D ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Department of Orthopedic Surgery   (Germany)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; GABRE PROTEIN, HUMAN; MICRORNA; MIRN224 MICRORNA, HUMAN; MIRN452 MICRORNA, HUMAN; TUMOR MARKER;

AGED; CELL LINE; CELL MOTION; CELL SURVIVAL; COHORT ANALYSIS; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSTATECTOMY; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; TUMOR CELL LINE; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, GABA-A; TUMOR MARKERS, BIOLOGICAL;

EID: 84899013734     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2642     Document Type: Article

References (50)

1. Prensner JR, Rubin MA, Wei JT, ChinnaiyanAM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4:127rv3.
2. Wilke K, Gaul R, Klauck SM, Poustka A. A gene in human chromosome band Xq28 (GABRE) defines a putative new subunit class of the GABAA neurotransmitter receptor. Genomics 1997;45:1-10.
3. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009;181:1678-85.
4. Banez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with postradical prostatectomy prostate cancer. J Urol 2010;184:149-56.
5. Goering W, Kloth M, Schulz WA. DNA methylation changes in prostate cancer. Methods Mol Biol 2012;863:47-66.
6. Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 2012;110:56-62.
7. Troyer DA, Lucia MS, de Bruine AP, Mendez-Meza R, BaldewijnsMM, Dunscomb N, et al. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev 2009;18:2717-22.
8. D'Hulst C, Atack JR, Kooy RF. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov Today 2009;14: 866-75.
9. Neelands TR, Fisher JL, Bianchi M, Macdonald RL. Spontaneous and gamma-aminobutyric acid (GABA)-activated GABA(A) receptor channels formed by epsilon subunit-containing isoforms. Mol Pharmacol 1999;55:168-78.
10. Azuma H, Inamoto T, Sakamoto T, Kiyama S, Ubai T, Shinohara Y, et al. Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Cancer Res 2003;63:8090-6.
11. Abdul M, McCray SD, Hoosein NM. Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer. Acta Oncol 2008;47:1546-50.
12. Drell TLt, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003;80:63-70.
13. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012;6: 590-610.
14. Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 2013;59:261-9.
15. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012;31:978-91.
16. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 2008;68:1152-64.
17. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells andtumor-suppressive functionsof let-7.CancerRes2012;72:3393-404.
18. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, et al. HsamiR- 375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol 2012;226:108-19.
19. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
20. White NM, Chow TF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, et al. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer 2010;102:1244-53.
21. Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 2010;6:521-9.
22. Li Q, Wang G, Shan JL, Yang ZX, Wang HZ, Feng J, et al. MicroRNA- 224 is upregulated inHepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol 2010;25:164-71.
23. Boguslawska J, Wojcicka A, Piekielko-Witkowska A, Master A, Nauman A. MiR-224 targets the 30UTR of type 1 50-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PloS ONE 2011;6:e24541.
24. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009;9:374.
25. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 2010;4:51.
26. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, et al. MiRNA expression in urothelial carcinomas: important roles of miR- 10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009;124:2236-42.
27. Vestergaard EM, Nexo E, Torring N, Borre M, Orntoft TF, Sorensen KD. Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int J Cancer 2010;127:1857-65.
28. Sorensen KD, Abildgaard MO, Haldrup C, Ulhoi BP, Kristensen H, Strand S, et al. Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer. Br J Cancer 2013;108:420-8.
29. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013;31:3250-8.
30. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
31. Bert SA, Robinson MD, Strbenac D, StathamAL, Song JZ, Hulf T, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell 2013;23:9-22.
32. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011;38:1093-101.
33. Cao P, Deng Z,Wan M,Huang W,Cramer SD, Xu J, et al.MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010;9:108.
34. Zhang X, Zhang R, Zheng Y, Shen J, Xiao D, Li J, et al. Expression of gamma-aminobutyric acid receptors on neoplastic growth and prediction of prognosis in non-small cell lung cancer. J Transl Med 2013;11:102.
35. Huang L, Ting D, Lin X, Zhao XH, Chen XT, Wang CJ, et al. MicroRNA- 224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochem Biophys Res Commun 2012;24;425:127-33.
36. Li W, Wang X, Li B, Lu J, Chen G. Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer. Urology 2012;80:952 e1-7.
37. Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008;10:1285-94.
38. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A firstgeneration multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9.
39. Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 2008;99:939-48.
40. Kojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 2014;59:78-87.
41. Steketee K, Ziel-van der Made AC, van der Korput HA, Houtsmuller AB, Trapman J. A bioinformatics-based functional analysis shows that the specifically androgen-regulated gene SARG contains an active direct repeat androgen response element in the first intron. J Mol Endocrinol 2004;33:477-91.
42. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009;25:13-20.
43. Archangelo LF, Greif PA, Holzel M, Harasim T, Kremmer E, Przemeck GK, et al. The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Mol Oncol 2008;2:356-67.
44. Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 2010;126:2012-24.
45. Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): posttranscriptional drivers of cancer progression? Cell Mol Life Sci 2013;70:2657-75.
46. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012;481:190-4.
47. de Carvalho AV, Bonamigo RR, da Silva CM, Pinto AC. Positivity for HLA DR1 is associated with basal cell carcinoma in renal transplant patients in southern Brazil. Int J Dermatol 2012;51:1448-53.
48. Jang SY, Jang SW, Ko J. Regulation of ADP-ribosylation factor 4 expression by small leucine zipper protein and involvement in breast cancer cell migration. Cancer Lett 2012;314:185-97.
49. Woo IS, Eun SY, Jang HS, Kang ES, Kim GH, Kim HJ, et al. Identification of ADP-ribosylation factor 4 as a suppressor of N- (4-hydroxyphenyl)retinamide- induced cell death. Cancer Lett 2009; 276:53-60.
50. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008;7:1214-24.